Articles By Jack Cush, MD
Psoriasis and Nonalcoholic Fatty Liver Disease
A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).
Read Article
Increasing Corticosteroid Use in Non-Hospitalized COVID-19
JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.
Read Article
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists.
Read Article
Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?
SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.
Read Article
Amitriptyline and FDA Treatments for Fibromyalgia
Both old and newer pharmacological treatments for fibromyalgia are often promoted; but a recent systematic review and network meta-analysis showed that duloxetine had higher efficacy in pain and depression, while amitriptyline had higher efficacy in treating sleep, fatigue, and quality of life outcomes.
Read Article
The Inflammation Reflex (5.20.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.
Read Article
Biologic Persistence in Psoriatic Arthritis and Psoriasis
Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.
Read Article
Inflammatory Arthritis Spread by ATP and Neural Crosstalk
A novel study from the Journal of Experimental Medicine suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk.
Read Article
Relevance of Raynaud’s in Systemic Sclerosis
Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.
Read Article
RNL 2022: Spondyloarthritis Spectrum
This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis. - Microbiome in Spondyloathritis - Jose Scher, MD - Axial Psoriatic Arthritis - Philip Mease, MD - Juvenile Spondyloathritis - Pamela Weiss, MD
Read Article